Enzymatica AB: Positive Q3 Results and Strategic Growth
Enzymatica AB has reported a promising performance for the third quarter of 2025, demonstrating notable growth in its sales in Sweden. Under the leadership of Claus Egstrand, the company has been focused on expanding its international presence while ensuring robust commercial conditions for its products.
Financial Highlights of Q3
For the third quarter, net sales have reached SEK 15.0 million, showcasing an increase from SEK 12.6 million compared to the previous year. Despite the growth in sales, the operating result stands at SEK -8.2 million, up from SEK -6.4 million last year, reflecting the ongoing investment in expansion efforts. Additionally, earnings per share were reported at SEK -0.03, slightly better than SEK -0.04 from the previous quarter. Meanwhile, the cash flow from operating activities totaled SEK -12.2 million, which is an improvement from SEK -13.6 million reported last year.
Year-to-Date Performance
When analyzing the year-to-date figures, Enzymatica achieved net sales of SEK 35.6 million, an increase from SEK 28.4 million compared to last year. The operational results show a loss of SEK -41.1 million, which is slightly worse than the previous year’s SEK -38.3 million. In terms of cash flow, there was a total of SEK -41.4 million from operating activities, reflecting the company's ongoing investment phase.
CEO's Insights on Growth
CEO Claus Egstrand remarked on the sales growth in Sweden, stating, "In the third quarter, we saw strong sales growth, while partner discussions are taking time as we work to secure the right commercial terms for the product." This reflects the company’s commitment to maintaining its standards while navigating the complexities of international expansion.
Significant Events During the Quarter
A pivotal change occurred as Sana Alajmovic was appointed the new Chief Executive Officer, replacing Claus Egstrand, who will take a position on the Board of Directors to ensure a smooth transition and continuity within the business operations. Alajmovic is expected to assume her position by January 31, 2026.
Extraordinary General Meeting Insights
On August 22, an Extraordinary General Meeting was convened where Claus Egstrand was elected to the Board. The meeting also initiated a long-term incentive program for the management, which will involve up to 2,000,000 warrants, redeemable in the fourth quarter of 2028.
Post-Quarter Developments
After the quarter concluded, on October 13, Enzymatica announced the appointment of Holger Lembrér as the new CFO, effective no later than April 2026. This decision signifies the company’s strategic approach to enhancing its financial operations moving forward.
Partnership with Swedish Biathlon Federation
Enzymatica has also ventured into a new partnership with the Swedish Biathlon Federation, serving as the federation's official supplier. This collaboration aims to alleviate upper respiratory infections in elite biathletes, especially with the upcoming Milan Winter Olympics in 2026.
Product Innovations
On the product front, Enzymatica has launched ColdZyme Eucalyptus in October, adding to its well-regarded product line. This new variant promises the same clinically proven efficacy as its predecessors and provides an alternative to the existing flavors of menthol and strawberry.
Collaboration with GB Snowsport
Additionally, Enzymatica announced a partnership with GB Snowsport, reinforcing its commitment to support elite athletes in their preparation for upcoming competition seasons. The focus remains on minimizing the effects of virus-induced respiratory infections, showcasing the company's dedication to athlete health and performance.
Contact Information
For further inquiries about Enzymatica AB and its operations, please reach out to Claus Egstrand, CEO. Phone: +44 7780 22 8385.
Frequently Asked Questions
What were the key financial highlights for Q3 2025?
Enzymatica reported net sales of SEK 15.0 million and an operating result of SEK -8.2 million for Q3 2025.
Who is the new CEO of Enzymatica?
Sana Alajmovic has been appointed as the new CEO, taking over from Claus Egstrand.
What significant partnerships did Enzymatica announce?
The company entered a partnership with the Swedish Biathlon Federation and GB Snowsport to support athletes in competition.
What product was launched recently by Enzymatica?
ColdZyme Eucalyptus was launched as a new addition to their product range in October 2025.
Who can be contacted for more information about the company?
Claus Egstrand, the CEO, is available for contact at +44 7780 22 8385 for further inquiries.
